AbCellera Biologics Receivables 2019-2025 | ABCL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AbCellera Biologics receivables from 2019 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AbCellera Biologics receivables from 2019 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$245.4B
Amgen (AMGN)	$157.5B
Gilead Sciences (GILD)	$146.4B
Vertex Pharmaceuticals (VRTX)	$100B
Bristol Myers Squibb (BMY)	$98.1B
CSL (CSLLY)	$85.5B
GSK (GSK)	$79.6B
Regeneron Pharmaceuticals (REGN)	$60.8B
Alnylam Pharmaceuticals (ALNY)	$59.9B
Argenex SE (ARGX)	$40.5B
BioNTech SE (BNTX)	$27.1B
Insmed (INSM)	$26.9B
Royalty Pharma (RPRX)	$20.9B
Biogen (BIIB)	$19.9B
Incyte (INCY)	$16.6B
Illumina (ILMN)	$15.5B
Genmab (GNMSF)	$15.3B
Genmab (GMAB)	$15B
Ascendis Pharma (ASND)	$11.9B
BioMarin Pharmaceutical (BMRN)	$11B
Moderna (MRNA)	$10.9B
QIAGEN (QGEN)	$10.8B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Exelixis (EXEL)	$10.2B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.5B
Bio-Techne Corp (TECH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Halozyme Therapeutics (HALO)	$8.1B
Roivant Sciences (ROIV)	$8B